SAB Biotherapeutics
SABS
SAB Biotherapeutics (SABS) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Barclays | Initiated Coverage | Overweight | $13.00 | Jun 24, 2026 |
| Chardan Capital | Maintained | Buy | $16.00 from $14.00 | Jun 17, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 | Jun 15, 2026 |
| Leerink Partners | Maintained | Outperform | $12.00 from $7.00 | Jun 15, 2026 |
| Citigroup | Initiated Coverage | Buy | $11.00 | May 22, 2026 |
| Jefferies | Initiated Coverage | Buy | $11.00 | May 20, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 from $7.00 | May 12, 2026 |
| Rodman & Renshaw | Maintained | Buy | $13.00 | May 11, 2026 |
| Chardan Capital | Maintained | Buy | $14.00 from $12.00 | Mar 11, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $7.00 from $9.00 | Mar 10, 2026 |
| UBS | Initiated Coverage | Buy | $7.00 | Jan 7, 2026 |
| Guggenheim | Initiated Coverage | Buy | $15.00 | Dec 19, 2025 |
| Chardan Capital | Maintained | Buy | $12.00 | Dec 18, 2025 |
| Chardan Capital | Maintained | Buy | $12.00 | Nov 17, 2025 |
| Chardan Capital | Maintained | Buy | $12.00 | Sep 19, 2025 |
| Leerink Partners | Initiated Coverage | Outperform | $7.00 | Sep 17, 2025 |
| Chardan Capital | Maintained | Buy | $12.00 from $20.00 | Aug 8, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $9.00 from $10.00 | Jul 22, 2025 |
| Chardan Capital | Maintained | Buy | $20.00 | May 15, 2025 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $10.00 | May 14, 2025 |
Frequently asked questions
What is the latest analyst rating on SABS?
On Jun 24, 2026, Barclays initiated coverage of SAB Biotherapeutics at Overweight with a price target of $13.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.